Haemonetics (HAE) has been benefiting from business growth within Plasma, Hospital and Hemostasis Management. New launches are also aiding growth. The stock carries a Zacks Rank #1 (Strong Buy).Haemonetics’ hospital portfolio is evolving and helping to create new opportunities for growth and diversification. Each of the four product lines has a leading market position and a mission of helping hospitals and clinicians provide the highest standard of patient care while at the same time reducing operating and ...